Evidence map›Paper›PMID 30760918›Full record

ReviewCellular & molecular immunology2019

Emerging approaches and technologies in transplantation: the potential game changers.

Anil Dangi, Shuangjin Yu, Xunrong Luo

Abstract readReview
In one paragraph

Review in Cellular & molecular immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Nanoparticle-Based Interventions for Liver Transplantation.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Therapeutic Strategies for MutantBrain sciences · 2021
    Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anil Dangi *Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Shuangjin Yu *Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Xunrong LuoDivision of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC, USA. xunrong.luo@duke.edu.

Funding

Protein-Releasing Microporous Scaffolds for Cell Replacement TherapyR01EB009910 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUO, XUNRONG, SHEA, LONNIE D · 2010 to 2018
$3.5M
Modeling concurrent cytomegalovirus infection and transplantation toleranceR01AI114824 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUO, XUNRONG · 2016 to 2020
$1.4M
NIAID NIH HHS R01 AI114824NIBIB NIH HHS R01 EB009910
6 · The paper itself

Abstract

Newly emerging technologies are rapidly changing conventional approaches to organ transplantation. In the modern era, the key challenges to transplantation include (1) how to best individualize and possibly eliminate the need for life-long immunosuppression and (2) how to expand the donor pool suitable for human transplantation. This article aims to provide readers with an updated review of three new technologies that address these challenges. First, single-cell RNA sequencing technology is rapidly evolving and has recently been employed in settings related to transplantation. The new sequencing data indicate an unprecedented cellular heterogeneity within organ transplants, as well as exciting new molecular signatures involved in alloimmune responses. Second, sophisticated nanotechnology platforms provide a means of therapeutically delivering immune modulating reagents to promote transplant tolerance. Tolerogenic nanoparticles with regulatory molecules and donor antigens are capable of targeting host immune responses with tremendous precision, which, in some cases, results in donor-specific tolerance. Third, CRISPR/Cas9 gene editing technology has the potential to precisely remove immunogenic molecules while inserting desirable regulatory molecules. This technology is particularly useful in generating genetically modified pigs for xenotransplantation to solve the issue of the shortage of human organs. Collectively, these new technologies are positioning the transplant community for major breakthroughs that will significantly advance transplant medicine.

Indexed as

Transplantation ToleranceAnimalsAnimals, Genetically ModifiedCRISPR-Associated Protein 9Gene EditingHumansImmunosuppression TherapyNanotechnologyRNA-SeqSingle-Cell AnalysisSwineTranscriptomeTransplantationTransplantation, HeterologousCRISPR-Associated Protein 9Crisper Cas9NanotechnologySingle cell sequencingTransplantation

Identifiers

PMID30760918
PMCPMC6462010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.